Overview

The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Contr

Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
To compare the impact on recurrence risk of adjuvant TAI and adjuvant TACE for patients with HCC and PVTT after hepatectomy.
Phase:
Phase 3
Details
Lead Sponsor:
Sun Yat-sen University
Treatments:
Calcium
Calcium, Dietary
Cisplatin
Epirubicin
Ethiodized Oil
Leucovorin
Levoleucovorin
Oxaliplatin